Peng Tian

Sep 14, 2024 | preprints.org | Peng Tian |Mingxu Wang |Jianjun Yu |Weipin Li

Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 13 September 2024 / Approved: 14 September 2024 / Online: 14 September 2024 (11:37:43 CEST) Tian, P.; Han, Y.; Li, W.; Yang, X.; Wang, M.; Yu, J. New Design Scheme and Application of Fresnel Lens for Broadband Photonics Terahertz Communication. Preprints 2024, 2024091140. https://doi.org/10.20944/preprints202409.1140.v1 Tian, P.; Han, Y.; Li, W.; Yang, X.; Wang, M.; Yu, J.

Feb 26, 2024 | mdpi.com | Xiang Li |Xin Zhang |Wei Zhao |Peng Tian

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jan 16, 2024 | biorxiv.org | Peng Tian |Jie Zheng |Yue Xu |Tao Wu

AbstractIntratumour heterogeneity is a major challenge that limits the effectiveness of anticancer therapies, thus compromising treatment outcomes. Single-cell RNA sequencing (scRNA-seq) technology offers a means to capture gene expression profiles at a single-cell resolution, while drug perturbation experiments yield valuable pharmacological data at the bulk cell level.

Dec 17, 2023 | biorxiv.org | Peng Tian |Jie Zheng |Yue Quan Xu |Tao Wu

AbstractIntratumour heterogeneity is a major challenge that limits the effectiveness of anticancer therapies, thus compromising treatment outcomes. Single-cell RNA sequencing (scRNA-seq) technology offers a means to capture gene expression profiles at a single-cell resolution, while drug perturbation experiments yield valuable pharmacological data at the bulk cell level.

Dec 12, 2023 | biorxiv.org | Peng Tian |Jie Zheng |Yue Quan Xu |Tao Wu

AbstractIntratumour heterogeneity is a major challenge that limits the effectiveness of anticancer therapies, thus compromising treatment outcomes. Single-cell RNA sequencing (scRNA-seq) technology offers a means to capture gene expression profiles at a single-cell resolution, while drug perturbation experiments yield valuable pharmacological data at the bulk cell level.